Communiqués Alzinova AB

Actions

ALZ

SE0007413455

Recherche biotechnologique et médicale

Temps Différé Nasdaq Stockholm Autres places de cotation 12:31:37 22/07/2026			Varia. 5j.	Varia. 1 janv.
0,7390 ^SEK	+11,97%		+1,53%	-11,70%

24/06	Alzinova AB et Fujirebio signent une lettre d’intention en vue d’une éventuelle commercialisation d’un test sanguin de diagnostic de la maladie d’Alzheimer	CI
24/06	Alzinova signe un accord non contraignant avec Fujirebio en vue d’un test diagnostique sanguin potentiel pour la maladie d’Alzheimer	MT

Communiqués

07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
24/06	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
12/06	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
08/06	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
03/06	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ
26/05	Bulletin from the Annual General Meeting of Alzinova AB (publ)	AQ
25/05	The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today	AQ
21/05	Alzinova has received subscription commitments and underwriting commitments corresponding to 80 percent of the exercise of warrants of series TO4	AQ
20/05	Alzinova’s clinical results with ALZ-101 now published in Alzheimer’s Research & Therapy	AQ
13/05	Alzinova (Q1 Review): Scientific validation and strategic optionality	AQ
13/05	Alzinova publishes interim report for the period January – March 2026	AQ
12/05	Interview with Dr. Marwan Sabbagh – why ALZ-101 represents a next-generation approach in Alzheimer’s Disease	AQ
11/05	Alzinova’s clinical results with ALZ-101 to be published in scientific journal	AQ
30/04	Alzinova changes the date of its interim report Q1	AQ
23/04	Alzinova publishes annual report for 2025	AQ
22/04	NOTICE OF ANNUAL GENERAL MEETING IN ALZINOVA AB (PUBL)	AQ
08/04	Alzinova initiates collaboration with Amsterdam UMC to develop blood-based Alzheimer’s diagnostic test	AQ
25/03	Alzinova: Cash secured, but execution remains key – Q4 review	AQ
25/03	Alzinova (Q4 Review): Extended runway, still focus on deal	AQ
25/03	Alzinova publishes year-end report 2025	AQ
16/03	Alzinova’s Board of Directors resolves on a directed issue of units to underwriters in connection with the completed rights issue	AQ
05/03	Alzinova to participate in several international industry and investor events during spring and summer 2026	AQ
25/02	Alzinova announces final outcome of the rights issue	AQ
23/02	Alzinova announces preliminary outcome of the rights issue	AQ